Abstract:It has been well established the long-term safety and efficacy of hypofractionated whole-breast irradiation (H-WBI) in randomized trials, but little is known about the acute toxic effects experienced by patients treated with H-WBI and simultaneous boost of the tumor bed (TB). We herein assess the acute toxicity in patients treated with H-WBI and simultaneous boost of the TB after breast conserving surgery. (Clinicaltrials.gov : NCT02617043) From April 2015, 151 patients enrolled on an IRB-approved prospective study to assess the efficacy and toxicity of hypofractionated RT combined with simultaneous boost of TB in patients with breast conserving treatment. All patient received total dose of 40 Gy/15 Fx for whole breast, combined with simultaneous boost of TB, 3.2 Gy/Fx, total dose of 48 Gy/15 Fx. Simple intensity-modulated radiotherapy (sIMRT) treatment planning were applied in the whole set of patients. The acute toxicity effects were assessed according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 4.0. From April 2015 to December 2015, 151 patients with T1-2N0M0 tumors were consecutively and prospectively enrolled into study. The median age was 45 years old (range, 25-70 years). One hundred eleven (73.5%) patients had T1 tumors and 40 (26.5%) patients had T2. Among them, 88 (58.3%) patients received chemotherapy, including anthracycline, paclitaxel and platinum. One hundred thirteen (74.8%) patients were hormone receptor positive and 109 (72.2%) patients received adjuvant hormone therapy. When the acute toxicity effects of radiotherapy were assessed, 8 (5.3%) of them had no obvious acute physician-assessed skin reaction. 120 (79.5%) and 23 (15.2%) patients had Grade 1 and Grade 2 radiation dermatitis, respectively. Most of them showed skin erythema or day desquamation. Nine patients had moist desquamation mainly in the nipple and areola area, and twenty-one patients had mild lymphedema of breast. No grade ≥3 radiation dermatitis or pneumonitis was observed during treatment. The median treatment time of radiotherapy was 20 days (range, 17-25 days). Hypofractionated whole breast irradiation combined with simultaneous boost of the tumor bed can be well tolerated in patients with early breast cancer, in terms of dermatitis, lymphedema, and pneumonitis. Long term follow up of local control need to be identified in the future.

Clinical Results of Phase 2 Study of Whole-Breast Irradiation with Simultaneously Integrated Tumor Bed Boost (WBI-SIB): A Single-Center Experience

HELICAL TOMOTHERAPY FOR WHOLE-BRAIN IRRADIATION WITH INTEGRATED BOOST TO MULTIPLE BRAIN METASTASES: DOSIMETRIC ANALYSISANDCLINICAL OUTCOMES

Multibeam Inverse Intensity-Modulated Radiotherapy (IMRT) for Whole Breast Irradiation: a Single Center Experience in China.

Results of a Clinical Phase II Trial of Whole Breast Irradiation with a Hypofractionated Simultaneous Integrated Boost to the Tumor Bed after Breast-Conserving Surgery for Early Breast Cancer

Adjuvant Breast Radiotherapy Using a Simultaneous Integrated Boost for Early-Stage Breast Cancer: Results from a Phase II Trial

Long-Term Results of Partial Breast Irradiation After Breast-Conserving Surgery for Early Stage Breast Cancer: A Prospective Phase II Trial in China

Simultaneous integrated boost intensity-modulated radiotherapy post breast-conserving surgery: clinical efficacy, adverse effects, and cosmetic outcomes in breast cancer patients

Adjuvant Breast Inversely Planned Intensity-Modulated Radiotherapy with Simultaneous Integrated Boost for Early Stage Breast Cancer

Acute Toxicity Effect of Hypofractionated Whole-Breast Radiation Therapy with Simultaneous Boost of the Tumor Bed in Patients with Breast-Conserving Treatment

10-Year Outcomes of Concomitant Boost Irradiation Following Breast-conserving Surgery versus Sequential Boost for Early-stage Breast Cancer treatment

Quality of Life After Partial or Whole-Breast Irradiation in Breast-Conserving Therapy for Low-Risk Breast Cancer: 1-Year Results of a Phase 2 Randomized Controlled Trial

Whole-brain radiation therapy plus simultaneous integrated boost for brain metastases from breast cancers

Dosimetric character and curative effect of postoperative radiotherapy with tumor bed boost simultaneously using IMRT in early breast cancer patients

Intensity modulated radiotherapy for patients with early-stage breast cancer after breast-conserving surgery pins 122 cases analysis

Dosimetric Comparison of the Simultaneous Integrated Boost in Whole-Breast Irradiation after Breast-Conserving Surgery: Imrt, Imrt Plus an Electron Boost and Vmat

A prospective study of intensity-modulated radiotherapy with integrated boost after breast conservative surgery in breast cancer patients

Simultaneous Integrated Boost in Breast Conserving Radiotherapy: is Replanning Necessary Following Tumor Bed Change?

Comparison of clinical efficacy between simultaneous integrated boostintensity-modulated radiotherapy (SIB-IMRT) and late-course boost intensity-modulated radiotherapy (LB-IMRT) for early-stage breast cancer after breast-conserving surgery

Quality-of-Life Outcomes from NRG/NSABP B-39/RTOG 0413: Whole-breast Irradiation vs Accelerated Partial-breast Irradiation after Breast Conserving Surgery.

Simultaneous Integrated Boost Intensity-Modulated Radiotherapy For Locally Advanced Non-Small Cell Lung Cancer In Chinese Population: A Retrospective Study

Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer